October 15th, 2017
•Ivacaftor and ivacaftor-lumacaftor combination are two new CF drugs. However, there is still a dearth of understanding on their PK/PD and pharmacology. We present an optimized HPLC-MS technique for the simultaneous analysis of ivacaftor and its major metabolites, and lumacaftor.
Vidéos Connexes
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Sampling Strategies and Processing of Biobank Tissue Samples from Porcine Biomedical Models
Collecting Hair Samples for Hair Cortisol Analysis in African Americans
High-Throughput Analysis of Optical Mapping Data Using ElectroMap
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
Culture and Imaging of Human Nasal Epithelial Organoids